Literature DB >> 16026104

Optimizing treatment of hypothyroidism.

Nick Clarke1, Udaya M Kabadi.   

Abstract

Several thyroid hormone preparations are currently available, including levothyroxine sodium (thyroxine), liothyronine (triiodothyronine), and desiccated thyroid extract, as well as a combination of levothyroxine sodium and liothyronine. Levothyroxine sodium monotherapy at an appropriate daily dose provides uniform levels of both thyroxine and triiodothyronine in the circulation without diurnal variation. Therefore, it is the preparation of choice in most patients with hypothyroidism of both the primary and central types. A normal thyrotropin (TSH) level of 1-2 mU/L is considered the determinant of optimal daily levothyroxine sodium dose in patients with primary hypothyroidism, whereas normal thyroxine and triiodothyronine levels in the mid or upper normal range may denote optimal replacement in patients with central hypothyroidism. Optimal daily levothyroxine sodium dose may be determined according to serum TSH level at the time of diagnosis of primary hypothyroidism. Initial administration of close to the full calculated dose of levothyroxine sodium is appropriate for younger patients, reducing the need for follow-up visits and repeated laboratory testing for dose titration. In the elderly and in patients with a history of coronary artery disease (CAD), the well established approach of starting with a low dose and gradually titrating to the full calculated dose is always the best option. Levothyroxine sodium can and should be continued in patients receiving treatment for CAD. Even minor over-replacement during initial titration of levothyroxine sodium should be avoided, because of the risk of cardiac events. Chronic over-replacement may induce osteoporosis, particularly in postmenopausal women, and should also be avoided.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 16026104     DOI: 10.2165/00024677-200403040-00003

Source DB:  PubMed          Journal:  Treat Endocrinol        ISSN: 1175-6349


  6 in total

1.  Microencapsulation of porcine thyroid cell organoids within a polymer microcapsule construct.

Authors:  Yipeng Yang; Emmanuel C Opara; Yingbin Liu; Anthony Atala; Weixin Zhao
Journal:  Exp Biol Med (Maywood)       Date:  2016-10-05

2.  Metabolic profiling provides a system understanding of hypothyroidism in rats and its application.

Authors:  Si Wu; Guangguo Tan; Xin Dong; Zhenyu Zhu; Wuhong Li; Ziyang Lou; Yifeng Chai
Journal:  PLoS One       Date:  2013-02-07       Impact factor: 3.240

Review 3.  Overt and subclinical hypothyroidism: who to treat and how.

Authors:  Deepak Khandelwal; Nikhil Tandon
Journal:  Drugs       Date:  2012-01-01       Impact factor: 11.431

4.  Generation of Thyroid Tissues From Embryonic Stem Cells via Blastocyst Complementation In Vivo.

Authors:  Qingsong Ran; Qiliang Zhou; Kanako Oda; Akihiro Yasue; Manabu Abe; Xulu Ye; Yingchun Li; Toshikuni Sasaoka; Kenji Sakimura; Yoichi Ajioka; Yasuo Saijo
Journal:  Front Endocrinol (Lausanne)       Date:  2020-12-14       Impact factor: 5.555

5.  Application of metabolomics and network analysis to reveal the ameliorating effect of four typical "hot" property herbs on hypothyroidism rats.

Authors:  Yang-Yang Wang; Yan-Ping Sun; Bing-You Yang; Qiu-Hong Wang; Hai-Xue Kuang
Journal:  Front Pharmacol       Date:  2022-08-25       Impact factor: 5.988

Review 6.  Polypharmacy in the HIV-infected older adult population.

Authors:  Lauren J Gleason; Amneris E Luque; Krupa Shah
Journal:  Clin Interv Aging       Date:  2013-06-21       Impact factor: 4.458

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.